Parkinsons disease (PD) is a disease that slowly damages the brain. People with PD may experience movement problems like shaking, slowness in movements and rigidity as well as mental and behavioural problems. PD affects one in 100 people over the age of 60. People with PD often have another disease in addition, like disease of the heart or blood vessels, diabetes or dementia. Despite the multiple symptomatic treatments available, a high unmet medical need remains because the treatment becomes less effective over time and due to accumulation of complications. Treatment of PD is highly individualized due to differences in how quick the brain damage and symptoms worsen, differences in response to treatment and differences in severity of movement problems depending on disease stage. Furthermore, treatment guidelines and reimbursement policies differ across regions. The purpose of this study is to describe the current treatments trends in new cases of PD in the UK and to identify factors that are associated with the specific treatment choices.
The study aims to describe the treatment patterns of Parkinsons Disease (PD) in the United Kingdom (UK) and to identify determinants of these treatment patterns. A cohort of patients with PD will be constructed from Clinical Practice Research Datalink (CPRD) data. Incident PD patients with a diagnosis code in CPRD data between 1 January 2007 and 31 March 2018 will be included. Kaplan-Meier estimates will be calculated for time to first symptomatic treatment overall and per treatment class and time to first switch or add-on treatment. Furthermore, Cox proportional-hazards regression analyses will be used to evaluate potential determinants of these time-to-event outcomes. Results will be presented overall and stratified by age groups, sex and calendar year.
Initiation of PD symptomatic treatment (overall and per treatment class)
- Switch or add-on of PD symptomatic treatment
- Time to titrate to dopa or dopa derivative stable dose
Loes Rutten-Jacobs - Chief Investigator - Roche
Loes Rutten-Jacobs - Corresponding Applicant - Roche
Preciosa Coloma - Collaborator - Roche
Spyros Roumpanis - Collaborator - F. Hoffmann - La Roche Ltd